Johnson & Johnson acquired Actelion for approximately $30 billion ($280 per share in cash) in an all-cash tender offer, gaining the world's leading pulmonary arterial hypertension franchise including Opsumit, Uptravi, and Tracleer. Actelion's drug discovery and early-stage R&D were spun out into a new Swiss company (Idorsia) with CHF 1 billion in capital.